In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VNUS Medical Technologies, Inc.

http://www.vnus.com

Latest From VNUS Medical Technologies, Inc.

Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.

Scrip Asks Innovation

Coronavirus Notebook: EMA Starts Review Of HIPRA’s COVID-19 Vaccine, Moderna To Set Up Australian mRNA Plant

There is no shortage of news relating to potential new COVID-19 treatments and vaccines. Among other things, zapnometinib, an antiviral compound being developed by German firm Atriva, has shown strong efficacy against Omicron in a Phase I study. Also, Sweden’s ISR and Iconovo have expanded their collaboration deal to accelerate the development of an inhaled COVID-19 vaccine.

Europe Australia

Deal Watch: AbbVie Partners With Gedeon Richter In Neuropsychiatry

Seeing strong sales with legacy Allergan’s Vraylar, AbbVie teams with Gedeon Richter on novel dopamine receptor modulators. AB Studio, CR Biopharma partner on COVID-19 neutralizing antibody.

Deal Watch Business Strategies

Mutation Quirk In NRx’s COVID-19 Vaccine Asset Could Help Fight VOCs

The firm’s live-virus COVID-19 vaccine candidate BriLife is entering a late-stage study following Phase II success, sparking hopes that its spontaneous mutations could parallel those of VOCs.

Vaccines Coronavirus COVID-19
See All

Company Information

UsernamePublicRestriction

Register